AP

APURES CO., LTD.

Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.

149300 | KO

Overview

Corporate Details

ISIN(s):
KR7149300006
LEI:
Country:
South Korea
Address:
경기도 평택시 청북읍 한산길 44, 평택시

Description

APURES CO., LTD. is a biotechnology company specializing in research and development solutions centered on its proprietary "MICROPIG" platform. This internationally registered minipig model, which is anatomically and physiologically similar to humans, serves as a foundation for the company's diverse offerings. APURES develops and supplies standard and transgenic MICROPIG models, along with a portfolio of derived bio-resources including organs, tissues, and standardized primary cells for cell-based assays. The company provides comprehensive non-clinical contract research organization (CRO) services, offering integrated in-vitro and in-vivo testing solutions tailored for new drug development. Additionally, APURES is advancing into therapeutic innovation, developing bio-materials for xenotransplantation and tissue engineering, and pursuing the development of its own pipeline of gene therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-11 00:00
주식등의대량보유상황보고서(약식)
Korean 80.7 KB
2025-08-05 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.6 KB
2025-07-28 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-07-28 00:00
주식등의대량보유상황보고서(일반)
Korean 110.8 KB
2025-07-18 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 33.6 KB
2025-07-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.8 KB
2025-07-10 00:00
주식등의대량보유상황보고서(약식)
Korean 104.6 KB
2025-07-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.6 KB
2025-07-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.6 KB
2025-06-24 00:00
주식등의대량보유상황보고서(일반)
Korean 91.3 KB
2025-06-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.7 KB
2025-06-20 00:00
주식등의대량보유상황보고서(일반)
Korean 91.3 KB
2025-06-16 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.7 KB
2025-06-12 00:00
주식등의대량보유상황보고서(일반)
Korean 104.4 KB
2025-06-09 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 97.0 KB

Automate Your Workflow. Get a real-time feed of all APURES CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for APURES CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for APURES CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.